Topical immunoregulatory therapy for psoriasis
Official title: A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis
Funded at Biotherapeutics, INC. · NIH-11419642 · Data updated 2026-11-12
A new topical treatment for psoriasis is being developed to safely reduce skin symptoms and improve quality of life.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, UNITED STATES) |
| Project start | September 20, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $191,331 |
| NIH project number | 5R44AR083730-03 |
| Project ID | NIH-11419642 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with moderate to severe psoriasis who are looking for non-systemic topical treatments.
✕Less likely to help
Patients with psoriasis who prefer or require systemic therapies or who have contraindications to topical formulations may not benefit from this specific therapy.
What this research studies
This project aims to bring a first-in-class topical therapy for psoriasis closer to patients by using advanced computer modeling together with lab and animal studies to understand how the drug works in skin. Researchers will study how the medicine distributes in tissues and how long it stays active, using mouse models of psoriasis to inform dosing and safety. The goal is to provide a safe, effective, easy-to-use treatment that patients can apply to affected skin. If successful, the work could pave the way for a future clinical testing pathway.
Why it matters
Potential benefit: If successful, patients with psoriasis could gain a new topical option with good skin clearance and tolerability.
How similar studies have gone: Previous topical therapies have shown disease reduction in animal models and early human studies, but first-in-class approaches require further confirmation.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Tubau-Juni, Nuria — Biotherapeutics, INC.
- Study coordinator: Tubau-Juni, Nuria
Related research
Other NIH-funded projects on the same topics.
-
Testing antiplatelet approaches in psoriasis to improve blood vessel health
A study at NYU School of Medicine will test antiplatelet strategies to reduce heart and blood vessel risk in adults with psoriasis.
-
Understanding psoriasis genetic signals across diverse populations
A study to uncover the genetic factors behind psoriasis in African American people using advanced genomic and epigenetic methods.
-
SerpinB3 and keratinocytes: a new path to understanding psoriasis
This NIH grant explores how a keratinocyte protein called SerpinB3 may drive plaque psoriasis, with the hope of finding new treatments for people with moderate-to-severe disease.
-
Role of a skin protein in psoriasis-related diabetes
A study explores how a skin inflammation signal may contribute to developing type 2 diabetes in people with psoriasis.
-
How satisfied people with plaque psoriasis are with their treatments
This project will try a new questionnaire called DermSat to measure treatment satisfaction among people with plaque psoriasis.
-
Anchored versus circulating enzyme therapy to calm psoriasis inflammation
Compares two ways of giving engineered enzyme medicines to help people with psoriasis reduce chronic skin inflammation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.